Schering-Plough Announces Expanded Stock Retention Guidelines for Senior Management

KENILWORTH, N.J., April 11 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) announced today a new governance action intended to strengthen the alignment of executives with the interests of shareholders.

"We are expanding the stock retention guidelines, which we believe are now among the strongest in our industry, for the Executive Management Team (including the five highest-paid executives)," said Hans W. Becherer, Chairman of the Compensation Committee of the Board of Directors.

"Schering-Plough executive compensation policies tie a significant percentage of compensation to performance. Further, a significant portion of total executive compensation is already paid in stock (rather than cash) to align management with shareholders. The policy we are announcing today further strengthens that alignment with shareholders, at a time when our industry and our company are under increasing challenge," said Becherer.

"The actions we are announcing today further strengthen our company in a challenging environment, as we continue with confidence to drive toward our goal of long-term high performance," said Fred Hassan, chairman and CEO.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

SOURCE Schering-Plough Corporation

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.